We recently showed that Src inhibition with the Abl/Src inhibitor bosutinib reduces dopamine catabolism and α-syn levels in patients with dementia with Lewy bodies and significantly improves activities of daily living (Pagan et al., 2022). Here, SRC is linked to dementia.